Patient-Specific Circulating Tumor DNA for Monitoring Response to Menin Inhibitor Treatment in Preclinical Models of Infant Leukemia
Notably, ctDNA analysis proved to be a superior predictor of MRD compared to PB assessment alone, especially in instances of low disease burden. These findings highlight the potential of ctDNA as a sensitive biomarker for monitoring treatment response and detecting MRD in infant MLL-r ALL.
Authors
- Narges Bayat (ORCID: https://orcid.org/0000-0002-1986-2845)
- Richard B. Lock (ORCID: https://orcid.org/0000-0002-3436-9071)
- J. Justin Gooding (ORCID: https://orcid.org/0000-0002-5398-0597)
- Louise Doculara
- Kathryn Evans (ORCID: https://orcid.org/0000-0001-8737-6358)
Institutions
- Cancer Institute of New South Wales (AU)
- UNSW Sydney (AU)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3390/cancers16233990
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.29
Funders
- Anthony Rothe Memorial Trust
- University of New South Wales
- Cancer Council NSW